Zydus receives final approvals from USFDA for Ivermectin Tablets USP
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The facility is expected to become operational by FY2028-29
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Subscribe To Our Newsletter & Stay Updated